HemOnc Today New York

The latest news from the annual meeting, including video perspective from faculty members and attendees.


Meeting News CoverageVideo

VIDEO: Intralesional monotherapies may not have a role for severe unresectable melanoma

March 19, 2016
NEW YORK — In a debate at HemOnc Today Melanoma and Cutaneous Malignancies, Robert H.I. Andtbacka, MD, CM, FACS, FRCSC, surgical oncologist…
Meeting News Coverage

Multiple gene mutations may predict recurrence in malignant melanoma

March 19, 2016
NEW YORK — Patients with primary malignant melanoma are at a higher risk for tumor recurrence if they have mutations in two or more…
Meeting News Coverage

Brain may become ‘just another organ’ in treatment of metastatic melanoma

March 19, 2016
NEW YORK — A new paradigm is evolving for the treatment of brain metastases from melanoma that involves a greater role of systemic therapy…
Meeting News CoverageVideo

VIDEO: Melanoma before, during pregnancy a ‘substantial problem’

March 19, 2016
NEW YORK —Vernon K. Sondak, MD, chair of the department of cutaneous oncology at Moffitt Cancer Center and a HemOnc Today Editorial Board…
Meeting News Coverage

Clinical trials ‘remain the priority’ for patients with uveal melanoma

March 19, 2016
NEW YORK — A greater understanding of disease biology has led to the development of novel immunotherapies and targeted therapies that hold…
Meeting News CoverageVideo

VIDEO: Combination immunotherapy may improve OS in metastatic melanoma

March 19, 2016
NEW YORK — Combination immunotherapy with CTLA-4 blockade plus anti–PD-1 inhibitors may effectively treat patients with metastatic…
Meeting News Coverage

Benefits, harms of routine skin cancer screening uncertain

March 19, 2016
NEW YORK — Whether public skin cancer screening or awareness campaigns have led to the observed improvements in melanoma detection and…
Meeting News Coverage

Intralesional therapy ‘here to stay’ for melanoma

March 19, 2016
NEW YORK — There are many ongoing monotherapy and combination trials of oncolytic agents, according to a speaker at HemOnc Today Melanoma and…
Meeting News CoverageVideo

VIDEO: Checkpoint blockade therapy may not be suitable for all

March 18, 2016
NEW YORK — Not all patients with melanoma should receive combination checkpoint inhibition with ipilimumab and nivolumab, Jeffrey S. Weber
Meeting News Coverage

Ipilimumab, interferon debated as standard adjuvant therapy for high-risk disease

March 18, 2016
NEW YORK — Two speakers at HemOnc Today Melanoma and Cutaneous Malignancies debated whether ipilimumab has replaced interferon as the standard…